---
id: aasld-hep-b-2024
title: "AASLD Practice Guidance on Hepatitis B Virus Infection"
short_title: "Hepatitis B"
organization: American Association for the Study of Liver Diseases
country: United States
url: https://journals.lww.com/hep/fulltext/2024/02000/aasld_practice_guidance_on_hepatitis_b_virus.12.aspx
specialty: hepatology
guideline_type: clinical-practice
evidence_system: aasld-grade
conditions:
  - Chronic Hepatitis B
  - Hepatitis B Virus Infection
  - HBV
tags:
  - hepatitis B
  - HBV
  - antiviral therapy
  - HCC surveillance
publication_date: 2024-02-01
previous_version_date: 2018-04-01
status: current
supersedes: aasld-hbv-2018
superseded_by: null
pdf_path: null
has_pdf: false
last_reviewed: 2025-01-01
---

## Scope

This practice guidance provides updated recommendations for the prevention, diagnosis, and management of chronic hepatitis B virus (HBV) infection.

## Key Recommendations

### Screening
- Universal adult screening recommended (at least once)
- High-risk populations: Immigrants from endemic areas, MSM, PWID, HIV+, household contacts
- HBsAg, anti-HBs, anti-HBc (total)

### Phases of Chronic HBV
- Immune tolerant (HBeAg+, high viral load, normal ALT)
- Immune active (elevated ALT, fluctuating viral load)
- Inactive carrier (HBeAg-, low/undetectable HBV DNA, normal ALT)
- Reactivation (HBeAg- chronic hepatitis)

### Treatment Indications
- Immune active hepatitis (elevated ALT + HBV DNA)
- Cirrhosis with detectable HBV DNA (any level)
- Significant fibrosis (≥F2)
- Immunosuppression/chemotherapy (prophylaxis)
- Extrahepatic manifestations

### First-Line Antiviral Therapy
- Entecavir 0.5mg daily (1mg if decompensated or prior lamivudine)
- Tenofovir DF (TDF) 300mg daily
- Tenofovir AF (TAF) 25mg daily (preferred for bone/renal risk)

### Treatment Goals
- Viral suppression (HBV DNA undetectable)
- ALT normalization
- HBeAg seroconversion (if HBeAg+)
- HBsAg loss (functional cure) - infrequent but ideal

### Duration
- Long-term/indefinite for most patients
- Discontinuation considered if: HBsAg loss, or HBeAg seroconversion with consolidation

### HCC Surveillance
- Ultrasound ± AFP every 6 months
- Cirrhosis regardless of treatment
- Non-cirrhotic at high risk (Asian males >40, Asian females >50, family history, Africans >20)

### Prevention
- Vaccination for all susceptible individuals
- HBIG + vaccine for perinatal exposure
- Antiviral for HBsAg+ pregnant women with high viral load
